Zevra Therapeutics (ZVRA) Retained Earnings (2014 - 2026)
Zevra Therapeutics (ZVRA) reported Retained Earnings of -$1.8 million for Q1 2026, down 2091.46% on a YoY basis from $90235.2 in Q1 2025, and down 135.21% quarter-over-quarter from -$764000.0 in Q4 2025.
Zevra Therapeutics (ZVRA) Retained Earnings (2014 - 2026) Analysis & Trends
Zevra Therapeutics has reported Retained Earnings for 13 years, with the latest figure at -$1.8 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 2091.46% year-over-year to -$1.8 million; the trailing twelve-month figure through Mar 2026 stood at -$1.8 million (down 2091.46% YoY), and the FY2025 full-year result was -$764000.0, down 221.08% from the prior year.
- Retained Earnings for Q1 2026 stood at -$1.8 million, down from -$764000.0 in the prior quarter.
- The five-year high for Retained Earnings was $631000.0 in Q4 2024, with the low at -$469.6 million in Q3 2024.
- Historically, Retained Earnings has averaged -$236.3 million across 5 years, with a median of -$320.3 million in 2023.
- Annual changes were most pronounced in 2023 — Retained Earnings plunged 353885.84% — and 2024, when it jumped 100.16%.
- Zevra Therapeutics' Retained Earnings stood at $113000.0 in 2022, then sank by 353885.84% to -$399.8 million in 2023, then jumped by 100.16% to $631000.0 in 2024, then tumbled by 221.08% to -$764000.0 in 2025, then slumped by 135.21% to -$1.8 million in 2026.
- The last three Retained Earnings figures came in at -$1.8 million (Q1 2026), -$764000.0 (Q4 2025), and -$434.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -279.00 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | 130.89 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -838.07 Mn |
| 10 | Zevra Therapeutics | 796.95 Mn | 596.33 Mn | 34.30 Mn | -1.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.80 Mn |
| Dec 31, 2025 | -764,000.00 |
| Sep 30, 2025 | -434.23 Mn |
| Jun 30, 2025 | -433.68 Mn |
| Mar 31, 2025 | -82,000.00 |
| Dec 31, 2024 | 631,000.00 |
| Sep 30, 2024 | -469.55 Mn |
| Jun 30, 2024 | -436.33 Mn |
| Mar 31, 2024 | -416.40 Mn |
| Dec 31, 2023 | -399.78 Mn |
| Sep 30, 2023 | -339.47 Mn |
| Jun 30, 2023 | -225,000.00 |
| Mar 31, 2023 | -320.34 Mn |
| Dec 31, 2022 | 113,000.00 |
| Jun 30, 2022 | -292.94 Mn |
| Dec 31, 2021 | -267.03 Mn |
| Sep 30, 2021 | -264.33 Mn |
| Jun 30, 2021 | -262.57 Mn |
| Mar 31, 2021 | -268.77 Mn |
| Dec 31, 2020 | -258.47 Mn |